142 related articles for article (PubMed ID: 12682407)
1. The potent anticancer compound ecteinascidin-743 (ET-743) as its 2-propanol disolvate.
Sainz-Diaz CI; Manzanares I; Francesch A; Garcia-Ruiz J
Acta Crystallogr C; 2003 Apr; 59(Pt 4):O197-8. PubMed ID: 12682407
[TBL] [Abstract][Full Text] [Related]
2. Synthetic studies on ecteinascidin-743: constructing a versatile pentacyclic intermediate for the synthesis of ecteinascidins and saframycins.
Jin W; Metobo S; Williams RM
Org Lett; 2003 Jun; 5(12):2095-8. PubMed ID: 12790537
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B.
Cuevas C; Pérez M; Martín MJ; Chicharro JL; Fernández-Rivas C; Flores M; Francesch A; Gallego P; Zarzuelo M; de La Calle F; García J; Polanco C; Rodríguez I; Manzanares I
Org Lett; 2000 Aug; 2(16):2545-8. PubMed ID: 10956543
[TBL] [Abstract][Full Text] [Related]
4. Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics.
Le VH; Inai M; Williams RM; Kan T
Nat Prod Rep; 2015 Feb; 32(2):328-47. PubMed ID: 25273374
[TBL] [Abstract][Full Text] [Related]
5. A practical synthesis of the ABC ring model of ecteinascidins.
Saito N; Tachi M; Seki R; Kamayachi H; Kubo A
Chem Pharm Bull (Tokyo); 2000 Oct; 48(10):1549-57. PubMed ID: 11045468
[TBL] [Abstract][Full Text] [Related]
6. Trabectedin: ET 743, ecteinascidin 743, Yondelis.
Drugs R D; 2003; 4(1):75-81. PubMed ID: 12568645
[No Abstract] [Full Text] [Related]
7. Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.
Cuevas C; Francesch A
Nat Prod Rep; 2009 Mar; 26(3):322-37. PubMed ID: 19240944
[TBL] [Abstract][Full Text] [Related]
8. Further insight into the DNA recognition mechanism of trabectedin from the differential affinity of its demethylated analogue ecteinascidin ET729 for the triplet DNA binding site CGA.
Marco E; David-Cordonnier MH; Bailly C; Cuevas C; Gago F
J Med Chem; 2006 Nov; 49(23):6925-9. PubMed ID: 17154523
[TBL] [Abstract][Full Text] [Related]
9. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove.
Zewail-Foote M; Hurley LH
J Med Chem; 1999 Jul; 42(14):2493-7. PubMed ID: 10411470
[TBL] [Abstract][Full Text] [Related]
10. Increased DNA binding specificity for antitumor ecteinascidin 743 through protein-DNA interactions?
García-Nieto R; Manzanares I; Cuevas C; Gago F
J Med Chem; 2000 Nov; 43(23):4367-9. PubMed ID: 11087561
[No Abstract] [Full Text] [Related]
11. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent.
Zewail-Foote M; Li VS; Kohn H; Bearss D; Guzman M; Hurley LH
Chem Biol; 2001 Nov; 8(11):1033-49. PubMed ID: 11731295
[TBL] [Abstract][Full Text] [Related]
12. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata.
Pommier Y; Kohlhagen G; Bailly C; Waring M; Mazumder A; Kohn KW
Biochemistry; 1996 Oct; 35(41):13303-9. PubMed ID: 8873596
[TBL] [Abstract][Full Text] [Related]
13. Enantioselective synthesis of saframycin A and evaluation of antitumor activity relative to ecteinascidin/saframycin hybrids.
Martinez EJ; Corey EJ
Org Lett; 1999 Jul; 1(1):75-7. PubMed ID: 10822537
[TBL] [Abstract][Full Text] [Related]
14. Differential rates of reversibility of ecteinascidin 743-DNA covalent adducts from different sequences lead to migration to favored bonding sites.
Zewail-Foote M; Hurley LH
J Am Chem Soc; 2001 Jul; 123(27):6485-95. PubMed ID: 11439034
[TBL] [Abstract][Full Text] [Related]
15. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action.
Aune GJ; Furuta T; Pommier Y
Anticancer Drugs; 2002 Jul; 13(6):545-55. PubMed ID: 12172500
[TBL] [Abstract][Full Text] [Related]
16. Ecteinascidin-743.
Held-Warmkessel J
Clin J Oncol Nurs; 2003; 7(3):313-9. PubMed ID: 12793338
[TBL] [Abstract][Full Text] [Related]
17. The antitumor agent ecteinascidin 743: characterization of its covalent DNA adducts and chemical stability.
Hurley LH; Zewail-Foote M
Adv Exp Med Biol; 2001; 500():289-99. PubMed ID: 11764956
[TBL] [Abstract][Full Text] [Related]
18. Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743.
Martinez EJ; Owa T; Schreiber SL; Corey EJ
Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3496-501. PubMed ID: 10097064
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and cytotoxic evaluation of some cribrostatin-ecteinascidin analogues.
Wright BJ; Chan C; Danishefsky SJ
J Nat Prod; 2008 Mar; 71(3):409-14. PubMed ID: 18278868
[TBL] [Abstract][Full Text] [Related]
20. A 3.(ET743)-DNA complex that both resembles an RNA-DNA hybrid and mimicks zinc finger-induced DNA structural distortions.
Marco E; García-Nieto R; Mendieta J; Manzanares I; Cuevas C; Gago F
J Med Chem; 2002 Feb; 45(4):871-80. PubMed ID: 11831898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]